Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03016871 · ClinicalTrials.gov registry record · Phase 2
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL
A Phase 2 study of Refractory Hodgkin Lymphoma and Recurrent Hodgkin Lymphoma, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 4
- Study locations
NCT03016871 is a Phase 2 study of Refractory Hodgkin Lymphoma and Recurrent Hodgkin Lymphoma that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 78 participants, above the 35-participant average among 11 other Refractory Hodgkin Lymphoma trials with a reported enrollment target (123% higher). The trial reports 4 study locations across 4 states.
The verdict
NCT03016871, a Phase 2 study of Refractory Hodgkin Lymphoma and Recurrent Hodgkin Lymphoma, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 4
- Study locations
Study Summary
This phase II trial studies the side effects of nivolumab and to see how well it works when given together with ifosfamide, carboplatin, and etoposide in treating patients with Hodgkin lymphoma that has come back (relapsed) and does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies such as nivolumab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as ifosfamide, carboplatin and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab, ifosfamide, carboplatin and etoposide may work better in treating patients with Hodgkin lymphoma.
Conditions Studied
Interventions
- DRUG Carboplatin
- OTHER Laboratory Biomarker Analysis
- DRUG Etoposide
- BIOLOGICAL Nivolumab
- DRUG Ifosfamide
Study Locations (4)
California
- City of Hope Medical Center - Duarte
Connecticut
- Yale University - New Haven
Texas
- M D Anderson Cancer Center - Houston
Washington
- Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2017-04-24 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03016871
The ClinicalTrials.gov registry entry for NCT03016871 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 35-participant average among 11 other Refractory Hodgkin Lymphoma trials with a reported enrollment target (123% higher). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Refractory Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT03016871 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Connecticut, Texas.
Frequently Asked Questions
What is clinical trial NCT03016871 about?
NCT03016871 is a clinical study titled "Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL". This phase II trial studies the side effects of nivolumab and to see how well it works when given together with ifosfamide, carboplatin, and etoposide in treating patients with Hodgkin lymphoma that has come back (relapsed) and does not respond to treatment (refractory). Immunotherapy with monoclona...
What is the current status of trial NCT03016871?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2017-04-24. Estimated completion is 2026-04-30.
What conditions does trial NCT03016871 study?
This clinical trial studies the following conditions: Refractory Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma.
What interventions are being tested in trial NCT03016871?
The interventions under investigation include: Carboplatin (DRUG), Laboratory Biomarker Analysis (OTHER), Etoposide (DRUG), Nivolumab (BIOLOGICAL), Ifosfamide (DRUG).
Who is sponsoring clinical trial NCT03016871?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03016871 being conducted?
This trial has 4 study locations across California, Connecticut, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
RECRUITING · Phase 2
-
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
RECRUITING · Phase 2
-
Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.